Skip to content
10-Q

Quarterly Report

VIROPHARMA INC

0001104659-13-079580

← back to feed
Filed
Oct 31, 2013 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2013 · Oct 18, 2013 65.91M sh
Shares Diluted Q3 2013 · Sep 30, 2013 71.75M sh
Shares Diluted Q3 2013 · Sep 30, 2013 65.4M sh
Shares Diluted Q3 2013 · Sep 30, 2012 67.61M sh
Shares Diluted Q3 2013 · Sep 30, 2012 72.19M sh
Capex Q3 2013 · Sep 30, 2013 $1.41M
Capex Q3 2013 · Sep 30, 2012 $1.17M
Cash And Equivalents Q3 2013 · Sep 30, 2013 $205.59M
Cash And Equivalents Q3 2013 · Dec 31, 2012 $175.52M
Cash And Equivalents Q3 2013 · Sep 30, 2012 $205.73M
Cash And Equivalents Q3 2013 · Dec 31, 2011 $331.35M
Stockholders Equity Q3 2013 · Sep 30, 2013 $727.91M
Stockholders Equity Q3 2013 · Dec 31, 2012 $757.04M
Current Liabilities Q3 2013 · Sep 30, 2013 $91.79M
Current Liabilities Q3 2013 · Dec 31, 2012 $114.03M
Total Liabilities Q3 2013 · Sep 30, 2013 $408.29M
Total Liabilities Q3 2013 · Dec 31, 2012 $462.91M
Current Assets Q3 2013 · Sep 30, 2013 $494.63M
Current Assets Q3 2013 · Dec 31, 2012 $453.42M
Total Assets Q3 2013 · Sep 30, 2013 $1.14B
Total Assets Q3 2013 · Dec 31, 2012 $1.22B
Eps Diluted Q3 2013 · Sep 30, 2013 $0.06
Eps Diluted Q3 2013 · Sep 30, 2013 −$0.91
Eps Diluted Q3 2013 · Sep 30, 2012 −$0.07
Eps Diluted restated Q3 2013 · Sep 30, 2012 $0.13
Eps Basic Q3 2013 · Sep 30, 2013 $0.06
Eps Basic Q3 2013 · Sep 30, 2013 −$0.91
Eps Basic Q3 2013 · Sep 30, 2012 −$0.07
Eps Basic restated Q3 2013 · Sep 30, 2012 $0.14
Sga Expense Q3 2013 · Sep 30, 2013 $45.5M
Sga Expense Q3 2013 · Sep 30, 2013 $134.46M
Sga Expense Q3 2013 · Sep 30, 2012 $44.29M
Sga Expense Q3 2013 · Sep 30, 2012 $123.34M
Rd Expense Q3 2013 · Sep 30, 2013 $18.09M
Rd Expense Q3 2013 · Sep 30, 2013 $52.45M
Rd Expense Q3 2013 · Sep 30, 2012 $16.55M
Rd Expense Q3 2013 · Sep 30, 2012 $48.57M
Operating Income Q3 2013 · Sep 30, 2013 $10.7M
Operating Income Q3 2013 · Sep 30, 2013 −$83.37M
Operating Income Q3 2013 · Sep 30, 2012 −$4.17M
Operating Income restated Q3 2013 · Sep 30, 2012 $35.37M
Cost Of Revenue Q3 2013 · Sep 30, 2013 $27.48M
Cost Of Revenue Q3 2013 · Sep 30, 2013 $85.5M
Cost Of Revenue Q3 2013 · Sep 30, 2012 $21.55M
Cost Of Revenue restated Q3 2013 · Sep 30, 2012 $81.72M
Stock Repurchased Q3 2013 · Sep 30, 2012 $151.9M